Compare InMode Ltd (INMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? InMode Ltd trades at $14.22 (market cap $809.93M), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 12.5× InMode Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| INMD | XBI | |
|---|---|---|
Market Cap | $809.93M | $10.11B |
Volume | 365,490 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $16.62 | $169.55 |
52-Week Low | $12.76 | $104.99 |
Typical Hold Time | 28 Days | 38 Days |
Enterprise Value | $313.27M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
